বঙ্গভবনে জাকজমকপূর্ণ অনুষ্ঠানে খ্যাতনামারা

স্বাধীনতা দিবসে সরকার প্রধান থেকে শুরু করে বিভিন্ন দলের রাজনীতিক, কূটনীতিক, যুদ্ধাহত মুক্তিযোদ্ধা, বীরশ্রেষ্ঠদের পরিবার এবং শিল্পী ও সাংস্কৃতিক ব্যক্তিত্বদের বঙ্গভবনে এক করলেন রাষ্ট্রপতি মো. আবদুল হামিদ।

স্বাধীনতা ও জাতীয় দিবস শনিবার বিকাল থেকে সন্ধ্যা পর্যন্ত সবার উপস্থিতিতে সরগরম ছিল বঙ্গভবনের সবুজ প্রাঙ্গণ। লাল-সবুজ পাতা দিয়ে তৈরি একটি পতাকা অনুষ্ঠানে আনে ভিন্নমাত্রা।
খ্যাতনামা শিল্পীদের দেশাত্মবোধক ও লোকগান এবং শিশুশিল্পী ও সশস্ত্র বাহিনীর বাদক দলের সংগীতের মূর্চ্ছনাও উপভোগ করেন সমবেতরা।
স্বাধীনতার ৪৫তম বার্ষিকীতে অতিথিদের সঙ্গে কুশল বিনিময় করেন রাষ্ট্রপতি আবদুল হামিদ; তার সঙ্গে ছিলেন প্রধানমন্ত্রী শেখ হাসিনা।
বিকাল পৌনে ৫টায় স্ত্রী রাশিদা খানমকে সঙ্গে নিয়ে বঙ্গভবনের মাঠে আসেন রাষ্ট্রপতি। তার খানিক আগে বঙ্গভবনে পৌঁছান প্রধানমন্ত্রী শেখ হাসিনা।
রাষ্ট্রপতি সস্ত্রীক মঞ্চে ওঠার সঙ্গে সঙ্গে শুরু হয় জাতীয় সঙ্গীত। এরপর পরস্পর কুশল বিনিময় করেন রাষ্ট্রপতি ও প্রধানমন্ত্রী। পরে যুদ্ধাহত মুক্তিযোদ্ধা ও বীরশ্রেষ্ঠদের পরিবারের সদস্যসহ আমন্ত্রিত অতিথিদের সঙ্গে শুভেচ্ছা বিনিময় করেন তারা।

যুদ্ধাহত মুক্তিযোদ্ধাদের শারীরিক অবস্থার খোঁজ-খবর নেওয়ার পাশাপাশি তাদের সার্বিক সহায়তার আশ্বাস দেন দুজনই।
এরপর স্বাধীনতা দিবসের কেক কাটেন রাষ্ট্রপতি ও প্রধানমন্ত্রী।
এরপর তারা মন্ত্রিপরিষদের সদস্য, বিভিন্ন দেশের রাষ্ট্রদূত, বিদেশি অতিথি, সুপ্রিম কোর্টের বিচারপতি, সংসদ সদস্য, গণমাধ্যমের সম্পাদক, তিন বাহিনীর প্রধানসহ সমারিক-বেসামরিক কর্মকর্তা, বিভিন্ন বিশ্ববিদ্যালয়ের উপাচার্যসহ আমন্ত্রিত অতিথিদের সঙ্গে শুভেচ্ছা বিনিময় করেন।
সংরক্ষিত এলাকায় প্রধানমন্ত্রী শেখ হাসিনার পাশে বসেন স্পিকার শিরীন শারমিন চৌধুরী।
বঙ্গভবনের এই সংবর্ধনা অনুষ্ঠানে ছিলেন প্রধান বিচারপতি সুরেন্দ্র কুমার সিনহা, জাতীয় পার্টির চেয়ারম্যান এইচএম এরশাদ, অর্থমন্ত্রী আবুল মাল আবদুল মুহিত, ডেপুটি স্পিকার ফজলে রাব্বী মিয়া।
শিল্পমন্ত্রী আমির হোসেন আমু, বাণিজ্যমন্ত্রী তোফায়েল আহমেদ, কৃষিমন্ত্রী মতিয়া চৌধুরী, বিমানমন্ত্রী রাশেদ খান মেনন, মুক্তিযুদ্ধ বিষয়ক মন্ত্রী আ ক ম মোজাম্মেল হক, স্বরাষ্ট্রমন্ত্রী আসাদুজ্জামান খাঁন কামাল, তথ্যমন্ত্রী হাসানুল হক ইনু, নৌমন্ত্রী শাজাহান খান, খাদ্যমন্ত্রী কামরুল ইসলামও অনুষ্ঠানে ছিলেন। ছিলেন প্রধানমন্ত্রীর উপদেষ্টা তৌফিক-ই-এলাহী চৌধুরী ও গওহর রিজভী।
আইনজীবী কামাল হোসেন, অ্যাটর্নি জেনারেল মাহবুবে আলম, সিইসি কাজী রকীবউদ্দীন আহমেদ অনুষ্ঠানে উপস্থিত ছিলেন।
আরও ছিলেন পররাষ্ট্র প্রতিমন্ত্রী শহারিয়ার আলম, শ্রম ও কর্মসংস্থান প্রতিমন্ত্রী মুজিবুল হক চুন্নু, ডাক ও টেলিযোগাযোগ প্রতিমন্ত্রী তারানা হালিম, ঢাকা উত্তর সিটি করপোরেশনের মেয়র আনিসুল হক।

কৃষক-শ্রমিক-জনতা লীগের সভাপতি কাদের সিদ্দিকী, সিপিবি সভাপতি মুজাহিদুল ইসলাম সেলিম, জাসদের একাংশের কার্যকরী সভাপতি মইন উদ্দীন খান বাদল, সাধারণ সম্পাদক নাজমুল হক প্রধানও ছিলেন।
জাতীয় পার্টির কো-চেয়ারম্যান জিএম কাদের, মহাসচিব রুহুল আমিন হাওলাদার, সাংসদ জিয়াউদ্দিন আহমেদ বাবলুও অনুষ্ঠানে ছিলেন।
বিএনপির কোনো নেতাকে দেখা না গেলেও সম্প্রতি এই দলটি ছেড়ে আসা শমসের মবিন চৌধুরীও অনুষ্ঠানে উপস্থিত ছিলেন।
ভারতের হাই কমিশনার হর্ষ বর্ধন শ্রিংলা, যুক্তরাষ্ট্রের রাষ্ট্রদূত মার্শা বার্নিকাট, মিশরের রাষ্ট্রদূত ও কূটনীতিক কোরের ডিন মাহমুদ ইজ্জত, ভুটানের রাষ্ট্রদূত পেমা সরেনসহ বিভিন্ন দেশের রাষ্ট্রদূত অনুষ্ঠানে উপস্থিত ছিলেন।
শিল্পী ফকির আলমগীর, বাপ্পা মজুমদার, ইয়াসমিন আলী, জিনাত জাহান মুন্নী, মৌটুসি ইসলাম, পুলক ও ভজন খ্যাপা তাদের গানের সুরে মোহিত করেন সবাইকে।   source  bdnews24

Read More

Latest IDERA Release Offers the Industry's Most Complete View of AWS Infrastructure

HOUSTON--(BUSINESS WIRE)--
IDERA, a leading provider of database lifecycle management solutions, today announced the newest release of Uptime Cloud Monitor. The updated product integrates 16 new AWS services, bringing the total to 22 and making Uptime Cloud Monitor the most comprehensive view of AWS services and infrastructure in the market.

This Smart News Release features multimedia. View the full release here: 

With AWS representing nearly 30 percent of the cloud infrastructure services market share, there is a growing need for more in-depth monitoring of AWS services. IDERA Uptime Cloud Monitor integrates with Amazon CloudWatch for AWS and enhances its capabilities through faster troubleshooting, long-term data storage and a comprehensive user interface.
Prior to this release, Uptime Cloud Monitor covered Billing Information, Elasticache, DynamoDB, Elastic Book Store, Elastic Cloud Compute and Relational Database Service, with the latter two ranking among the top six most-used AWS services, according to recent usage data. Four others in the top six include Simple Storage Service, Simple Queue Service, Route 53 DNS and Simple Notification Service, and are among the 16 newly added services that ensure as users grow and diversify their AWS footprint, Uptime Cloud Monitor grows with them.
“Since many of our customers use AWS to power their infrastructures, integrating more AWS metrics into our existing monitoring capabilities adds value and visibility for users,” said Beth Chauvin, product manager at IDERA. “Uptime Cloud Monitor is the ideal solution for a hybrid environment, including on premises servers and others hosted in the cloud. If someone is transitioning part of their server environment to the cloud, they can have critical AWS metrics at their disposal. Plus, our on-demand pricing allows customers to only pay for what they use, providing extensive monitoring benefits without enterprise-level costs.”
With the installation of Uptime Cloud Monitor’s lightweight agents, data can be collected more frequently, enabling users to perform real-time troubleshooting as errors and issues arise. Uptime Cloud Monitor can display, alert and store AWS metrics for up to one year, allowing for true historical trending. The updated product also offers a unified custom dashboard that is easy to navigate, allowing users to view 22 AWS services at-a-glance without switching to other applications.
“Uptime Cloud Monitor is a great AWS monitoring tool. No other monitoring software is able to accomplish what the IDERA solution can do,” said David Moore, operations manager at OneCloud Systems.


About IDERA
IDERA understands that IT doesn’t run on the network – it runs on the data and databases that power your business. That’s why we design our products with the database as the nucleus of your IT universe. Our database lifecycle management solutions allow database and IT professionals to design, develop, secure, monitor and improve data systems with complete confidence, whether in the cloud or on-premises. Serving more than 20,000 customers worldwide, we offer a diverse portfolio of free tools and educational resources to help you do more with less while giving you the knowledge to deliver even more than you did yesterday.

Read More

CORRECTING and REPLACING VIDEO Zoetis Receives FDA Approval for SimparicaTM (sarolaner) Chewables, a Once-Monthly Flea and Tick Medication for Dogs

FLORHAM PARK, N.J.--(BUSINESS WIRE)--
The b-roll video component of this multimedia news release has been updated and now includes the correct product packaging image for Simparica^TM. Please use this updated b-roll in communications related to this announcement.

This Smart News Release features multimedia. View the full release here: 

The release reads:

Zoetis Receives FDA Approval for Simparica^TM (sarolaner) Chewables, a Once-Monthly Flea and Tick Medication for Dogs

• Easy-to-administer chewable tablet delivers fast and persistent protection over 35 days from fleas and ticks, without losing efficacy at the end of the month
• Innovation from Zoetis targets growing demand for oral flea and tick medication

) today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica^TM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tasty chewable tablet, once-monthly Simparica offers fast and persistent protection from fleas and ticks, with peak performance that lasts for a full 35 days, without losing efficacy at the end of the month.¹
“Simparica is exciting for two reasons: it acts fast to kill fleas and ticks, and it maintains its efficacy all month long providing veterinarians and dog owners with confidence in continuous protection,” said Chris Adolph, DVM, DACVM (Parasitology), Zoetis. “Simparica kills fleas before they can reproduce and create a home infestation, and it kills ticks fast, which may help to reduce the likelihood of transferring pathogens that can cause tick-borne disease. Simparica continues to perform well, even on the last day of the month, whereas some of the other flea and tick products drop in efficacy at the end of their treatment period.”
“Simparica is the result of the collaboration of Zoetis scientists worldwide who share a commitment to develop innovative medicines that help address the most pressing needs of our veterinary customers and the animals in their care,” said Dr. Catherine Knupp, executive vice president and president, Research and Development at Zoetis. “We are excited to bring Simparica to veterinarians and dog owners in the United States.”
The global market for antiparasitics in pets was over $4.2 billion in 2014, with a compound annual growth rate of 5% over the previous five years, driven largely by growth of new oral products, according to Vetnosis.²
Simparica: A New Ectoparasiticide from Zoetis
The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, discovered and developed by Zoetis scientists. Simparica underwent extensive field safety and efficacy testing involving more than 900 dogs over a two- or three-month period. The dogs in these studies included both genders and many different breeds.¹
Clinical studies showed this isoxazoline started killing fleas in three hours, virtually eliminated fleas within eight hours, and it reduced the number of live fleas from ≥96.2% to 100% through day 35.¹ Simparica’s rapid onset of action means that fleas are killed before they have a chance to lay eggs,¹ preventing home infestations and providing relief to dogs suffering with flea allergy dermatitis.¹ Studies also showed that Simparica started killing ticks in eight hours,⁵ remaining ≥96.9% effective for 35 days against weekly re-infestations.^6-9
Simparica Killed Fleas Faster Than NexGard^®. In a comparative study, Simparica killed fleas faster than NexGard^® throughout the entire month. Simparica showed almost 100% flea kill eight hours after infestation, even at day 35, while NexGard^® started declining below 90% as early as day 21.⁴
Simparica Killed Ticks Faster Than NexGard^®. In a comparative study, Simparica killed ticks faster than NexGard^® throughout the entire month. Simparica maintained more than 90% effectiveness against the brown dog tick 24 hours after infestation at day 35, while efficacy for NexGard^® decreased to less than 80% by day 14.¹⁰
Simparica comes in a highly palatable liver-flavored chewable tablet. Zoetis expects to make Simparica available to veterinarians and pet owners in March 2016. The tablets will be available in 5 mg, 10 mg, 20 mg, 40 mg, 80 mg, and 120 mg dosage strengths.
For more information about Simparica and full Prescribing Information, visit:
IMPORTANT SAFETY INFORMATION
Simparica is for use only in dogs, 6 months of age and older. Simparica may cause abnormal neurologic signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures. Simparica has not been evaluated in dogs that are pregnant, breeding or lactating. Simparica has been safely used in dogs treated with commonly prescribed vaccines, parasiticides and other medications. The most frequently reported adverse reactions were vomiting and diarrhea. See full Prescribing Information at
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. 
References
1. Simparica (sarolaner) [package insert]. Kalamazoo, MI: Zoetis, Inc.; 2015.
2. Vetnosis, Animal Health Service: Parasiticides Report (Sept. 2015).
3. Zoetis. Overview of Clinical Safety in Client-Owned Dogs. 2015.
4. Zoetis. Comparative Speed of Kill of Sarolaner Administered Orally Against Induced Infestations of Ctenocephalides felis on Dogs (A160RZA-13-343, 2015).
5. Zoetis. Knock-down and Speed of Kill of Sarolaner Administered Orally Against Induced Infestations of Amblyomma maculatum on Dogs (A166C-US-13-318, 2014).
6. Zoetis. Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Amblyomma maculatum on Dogs (A166C-US-12-128, 2014; A166C-US-12-129, 2014).
7. Zoetis. Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Amblyomma americanum on Dogs (A166C-US-12-130, 2014; A166C-US-12-131, 2014).
8. Zoetis. Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Dermacentor variabilis on Dogs (A166C-US-12-132, 2013; A166C-US-12-133, 2013).
9. Zoetis. Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Rhipicephalus sanguineus on Dogs (A166C-US-12-135, 2013; A166C-IE-13-160, 2014; A166C-US-13-303, 2014; A166-AU-14-419, 2015).

10. Zoetis. Comparative Speed of Kill of Sarolaner Administered Orally Against Induced Infestations of Rhipicephalus sanguineus on Dogs (A162R-US-15-539, 2015).

Read More

Pent up dollar demand by jewellers to exert pressure on rupee: Experts

Mumbai, March 26 (IANS) Pent up demand for US dollars by the jewellery sector, coupled with a weak Chinese yuan, are expected to exert pressure on the Indian rupee during the upcoming week, experts said on Saturday.
"Keep an eye out for the bullion users, as once they get back to work, we can see a lot of pent up demand from these guys to emerge. This demand, along with demand from central bank can exert an upward pressure on dollar/rupee (pair)," Anindya Banerjee, associate vice president for currency derivatives with Kotak Securities, told IANS.
A sizeable section of jewellery industry players have been on strike against a proposed one percent hike in excise duty on non-silver jewellery in the union budget for 2016-17.
They have been on strike since March 2. The central government has constituted a panel to look into their demands.
"Chinese yuan has begun weakening which should be an added negative for rupee as well. We see USD/INR trade between 66.30-50 and 67.00/67-20 levels for the next week," Banerjee cited.
According to Banerjee, despite a mid-week sell-off towards 66.93, rupee managed to close nearly flat, due to relentless selling of US dollars from fronts like IT (information technology) companies.
"Demand for US dollars from RBI (Reserve Bank of India) has managed to build a floor under the US dollar for the moment, around 66.40-50 levels on spot," Banerjee elaborated.
"However going into the final quarter of the year, we can see more selling from large exporters."
During the truncated week ended March 23, the rupee weakened by 12 paise. The domestic currency markets were closed on Thursday-Friday, on account of Holi and Good Friday.
On a weekly basis, the rupee weakened by 12 paise to 66.62-63 (March 23) against a US dollar from its previous close of 66.50-51 (March 18) to a greenback.
Other analysts, attributed the rupee weakness on a strong US dollar. The US dollar has strengthened on the back of increased chances of a hike in US interest rates in April.
Even the Brussels attacks led investors to park their funds in safe assets like the US dollar.
Anand James, co-head, technical research desk with Geojit BNP Paribas Financial Services, told IANS: "The US dollar rose due to its appeal as a safe haven asset, pushing rupee towards the 67 mark."
However, there was an increased inflows by the foreign investors in the country's equity and bond markets.
The National Securities Depository Limited (NSDL) figures showed that the FPIs (Foreign Portfolio Investors) bought Rs.6,340.82 crore or $952.79 million in the equity and debt markets from March 21-23.
Data with stock exchanges disclosed that the FPIs invested in stocks worth Rs.3,468.68 crore during the week under review.
According to Hiren Sharma, senior vice president, currency advisory at Anand Rathi Financial Services, US Federal Reserve's slow rate vision and expansion of ECB's (European Central Bank) bond purchase program has motivated global equity investors.
"A revival in crude oil price has instigated a risk on mood presently. Since March 1st, a net of $1.6 billion inflow (mostly in equity) has come into India," Sharma told IANS.
"Rupee has a very strong support at 66.50-40 and resistance around 66.80-67.10. It is expected to remain in this range for penultimate week of FY15-16."

Read More

Shutdown observed in Himachal against excise duty on jewellery

Shimla, March 26 (IANS) Shops and commercial establishments were shut in nearly all towns of Himachal on Saturday, as traders protested against the union budgetary proposal to impose one percent excise duty on non-silver jewellery.
There was, however, no report of violence anywhere, a police official said.
The city's business hub The Mall wore a deserted look with shopkeepers joining the All-India strike by the trading community to protest against the excise duty.
However, eateries and shops selling essential items were exempted from the shut down.

Likewise, shops in prominent towns like Solan, Dharamsala, Kangra, Palampur, Mandi, Kullu, Manali, Una and Hamirpur remained partially closed for the day.

Read More

Immunetics BacTx® Test Helps Hospitals Meet FDA Proposed Changes in Platelet Bacteria Testing Practices

Immunetics today announced that the FDA has published updated Draft Guidance for Industry - “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion”. The proposed changes by the FDA in platelet bacteria testing practices cited the risks of bacterial contamination of platelets and the critical need for means to mitigate these risks. Immunetics BacTx^® Technology provides hospitals with a rapid, low cost, and proven solution to meet this new guidance.
The point-of-issue BacTx^® test allows hospitals to readily facilitate efficient testing of platelets with a rapid testing system for bacterial detection that meets the proposed FDA Guidance. The result is a safer platelet supply, providing transfusion services with a “last look” at the platelet unit just prior to transfusion.
Platelets are associated with a higher risk of sepsis and related fatalities than any other transfusable blood component. In the United States today, blood collection facilities must adhere to AABB Guidelines calling for every platelet to be tested using an FDA approved device. However, the risk of bacterial infection persists- the primary issue being sampling error, as most testing occurs early in the life of the platelet unit when bacteria counts may be too low to be captured during routine sampling. In the updated March 2016 Guidance document, the FDA indicates the need to improve the safety of platelet transfusions by secondary bacterial testing, and confirms that use of a rapid assay such as the BacTx^® test closer to the point of transfusion may mitigate these risks.

About Immunetics:
Immunetics Inc. offers state-of-the-art assay technology for infectious disease diagnosis and blood screening, and for more than ten years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. Immunetics is headquartered in Boston. The company’s mission is to deliver better, cost-efficient care through more accurate diagnosis.

Read More

Fitch Updates Criteria for Rating U.S. Auto Lease ABS

Fitch Ratings today published an updated Asset-Backed sector specific criteria report. There have been no material changes from the previous version, and therefore Fitch expects no impact on outstanding ratings.
This report updates and replaces the prior criteria report with the title 'Criteria for Rating U.S. Auto Lease ABS', dated Oct. 19, 2015.
The report presents Fitch's analytical approach to rating U.S. Auto Lease ABS and outlines the unique features of these transactions. Additionally, the report details key rating drivers associated with U.S. auto lease ABS as detailed below.
KEY RATING DRIVERS
Lease-End Residual Risk: Fitch's analysis of auto lease securitizations places a large focus on RV risk (see page 8). Fitch's RV risk analysis is driven by the issuer's historical RV loss rates and the potential volatility of the future used vehicle market. Historical worst case 12-18 month observations set the 'BBsf' rating level, with increased residual realization stresses given to investment-grade ratings, as described in this report.
Forward-Looking Approach to Loss Proxy: The credit risk analysis of auto leases is consistent with the approach for auto loan ABS. Fitch derives its base case credit loss proxy by examining fully amortized historical vintage loss curves, extrapolating incomplete vintage curves, matching future expectations with any relevant previous vintage data, and weighting by relevant pool credit characteristics. Additionally, a margin of safety is built into the base case by weighting previous recessionary vintages and adding adjustments for future unemployment expectations and/or wholesale vehicle market conditions, where applicable.
Concentration Risks: Auto lease pools and, notably, residual loss performance can be impacted by concentrations in the underlying leases or vehicles. Concentrations in vehicle model or segment can expose the trust to idiosyncratic risks affecting specific vehicle types. Additionally, material concentrations in the timing of lease maturities can expose the ABS performance disproportionately to periods of elevated residual losses. Fitch's quantitative analysis accounts for concentration risks, as described in this report.
Counterparty Exposures: Counterparty exposures can pose a risk to transactions if the relevant counterparties are a source of credit or performance weakness. Fitch's analysis includes a review of counterparties in accordance with our counterparty criteria titled 'Counterparty Criteria for Structured Finance and Covered Bonds' (published May 2014).
Seller/Servicer Operational Reviews: Disruption to servicing is a potential risk to the performance of auto loan ABS transactions. Fitch's analysis includes a review of the corporate and operational activities (originations, underwriting and servicing) of the seller/servicer(s) to assess operational risks and the ability of the servicer to assume the servicing role for the transaction.
Macroeconomic Risks: The economic environment can have a material impact and auto lease ABS ratings. Fitch takes into consideration the strength of the economy, as well as future expectations, by assessing key macroeconomic indicators correlated with lease performance (e.g. unemployment).
Additional information is available at

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY  IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE ''. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.  source   in.finance

Read More